Therapeutics
- Ref-No.Technology
- 01-00758Generation of EBV-specific T-cells using virus-like particles facilitates adoptive treatment of EBV-associated diseases
- 01-00830Novel antibody to carbonic anhydrase XII with therapeutic and diagnostic potential for solid tumors and eye diseases
- 01-00833VLP-based Epstein-Barr-Virus (EBV) vaccine
- 01-00937Empowering T and NK cells for adoptive cell transfer (ACT) through engineering with PD-1:4-1BB
- 01-00987DMD Gene Therapy Approach
- 01-EBV-VLPA VLP-based prophylactic EBV vaccine
- 02-00187Argyrin – A promising novel anti-cancer compound
- 02-00226Inhibition of Pathogenic Biofilms on natural or synthetic surfaces
- 02-00297Treatment of hepatocellular carcinoma
- 02-00311Cystobactamides – novel antibacterials against gram-negative pathogens
- 02-00312Novel Macrolide Antibiotics
- 02-00315Novel Chelocardin Derivatives – resistance breaking atypical tetracyclines with broad-spectrum antibiotic activity
- 02-00316Innovative Inhibitors of Pseudomonas Pathogenicity
- 02-00332Novel inhibitors of Pseudomonas aeruginosa LecB
- 02-00337Novel labyrinthopeptins as anti-viral agents
- 02-00350Novel Ratjadones as payloads in folate-, peptide-, and antibody-drug conjugates for the treatment of cancer
- 02-00351Increased Availability and Efficacy of Aminoglycosides
- 02-00352Carolacton as MTHFD2 inhibitor for cancer therapy
- 02-00353High-throughput Screening for anti-herpesviridae Drugs
- 02-00354Highly active Chlorotonil A Derivatives for the treatment of Malaria
- 02-00368Bivalent LecA Inhibitors Targeting Biofilm Formation of Pseudomonas aeruginosa
- 02-00376Overcoming resistance - Innovative broad-spectrum inhibitors of Metallo- β-lactamases
- 03-00092Substances modulating primary haemostasis
- 03-00207aNovel adjuvant class for use in immunotherapy and vaccination.
- 03-00207bNovel Peptide Drug enhancing Immune Response in Patients suffering from Immune Suppression and Leukopenia
- 03-00248Use of MAS-G-Protein-coupled receptor agonists for the treatment of Metabolic Syndrome
- 03-00251Stable Gene Transfer with Hyperactive Sleeping Beauty Transposase SB100X
- 03-00291Multiple Target T Cell Receptor
- 03-00295Highly Effective, Innovative Treatment of Acute Liver Failure
- 03-00302Aptamers for Treatment and Diagnosis of Autoantibody-based dilated Cardiomyopathy
- 03-00317Novel inhibitors of amyloid aggregate formation
- 03-00319Stimulation of arteriogenesis for the prevention of myocardial infarction
- 03-00352Repurposing Niclosamide for (neo-)adjuvant cancer therapy
- 03-00363Small molecule inhibitors of STOML3 promise to treat neuropathic pain
- 03-00367Targeting of Autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer’s and vascular dementia
- 03-00380Negative regulation of the IKK/NF-kB pathway activity by stabilisation of A20 mRNA – a new approach to treat inflammation
- 03-00393Novel TPH inhibitors for the treatment of fibrotic diseases and pulmonary arterial hypertension (PAH)
- 03-00397Plasma cell-specific antibodies targeting BCMA for the treatment of multiple myeloma and autoimmune diseases
- 03-00399/32-00019Human satellite cells as cell therapy for the treatment of muscle waisting disorders
- 03-00413Improved Sleeping Beauty Transposon System for gene therapy: SB100X/pT4
- 03-00417Novel BCMA-CAR for the treatment of multiple myeloma and non-Hodgkin lymphoma (NHL)
- 03-00430Selective Inhibitors of Genotoxic Stress-Induced IKK/NF-κB Pathways for Cancer Therapy
- 03-00446Novel CAR-T against CXCR5 for treatment of non-Hodgkin lymphoma
- 10-00026Novel Benzothiazinones, potent Tuberculosis antibiotics
- 10-00080Closthioamide- a new, unusual natural product with potent antibiotic activity against MRSA
- 10-00087Jagaricin – a novel antifungal natural compound
- 10-00088Bixiamycines –novel natural compounds with broad-spectrum antibiotic activity
- 10-00092Clostrubin - an unusual novel polyketide antibiotic
- 11-00054Innovative inhibitors of Notch trafficking and signalling for the treatment of cancer
- 11-00057Innovative Nerve Sheath Tumor Therapy
- 11-00060Novel treatment or prevention of age-related diseases extending lifespan
- 14-00020Anti-inflammatory, LPS-neutralizing and anti-bacterial agent against sepsis and other severe bacterial infections
- 14-00020bSALP peptides are potent broad-spectrum anti-viral agents
- 14-00097Antimicrobial, endotoxine-neutralizing and anti-inflammatory agent for wound healing and treatment of bacterial skin and soft-tissue infections
- 15-00302Novel inhibitor of mutated IDH1 in cancer therapy
- 15-00358COAT – an exceptionally efficient tumor vaccination approach
- 15-00371lncRNAs in therapy and diagnosis of disease related angiogenesis
- 15-00385LNCRNAS GADLOR 1 + 2 FOR DIAGNOSIS AND TREATMENT OF CARDIAC HYPERTROPHY
- 15-00394Efficient oncolytic anti-tumor therapy based on adenovirus
- 15-00432Scalable and Continuous Production of iPSC-derived Macrophages for Therapeutic and Research Applications
- 15-00436MicroRNA-125b-5p – a new treatment option for drug induced Acute Liver Failure
- 15-00461Novel treatment for septic diseases in newborns
- 18-00021Use of cPLA2a-Inhibitors in therapy of flavivirus infection
- 21-00027Ferulic acid derivative FAE-20 as efficient neuroprotective agent and memory enhancer
- 22-00009Quiescent B Cells for immune suppression in gene therapy
- 22-00017Functional IFN-gamma memory in CD4+ T cells: Method for improved T cell therapy and disease monitoring in autoimmune diseases
- 22-00020Bispecific antibodies for cell-type-specific TNF inhibition
- 23-00064Treating dementia and other brain disorders with natural glycans
- 23-00065Novel treatment of dementia-associated tauopathies
- 23-00069NMDAR targeted CAAR-T cell therapy
- 23-00080Sars-CoV2 Neutralizing Antibodies
- 32-00059T-cell therapy of MYD88L265P-dependent B-cell lymphoma
- 42-00022Stabilized minigastrin analogs for enhanced CCK2R targeting and applications in neuroendocrine tumor therapeutics and diagnostics
- 99-00126Novel gene therapy approach for cardiovascular diseases
